Summary
IDEXX Laboratories Inc. reported solid revenue growth of 8.7% to $626.3 million for the first quarter of 2020, compared to the same period in 2019. This growth was primarily driven by strong performance in the Companion Animal Group (CAG) segment, particularly in recurring revenue streams like consumables and reference laboratory services, which saw 10.0% organic growth. Despite the emerging impact of the COVID-19 pandemic starting in mid-March, which began to affect instrument placements and reference laboratory volumes, the company's diversified business segments, including Water and Livestock, Poultry & Dairy (LPD), also showed robust revenue increases. The company also took proactive steps to manage costs and enhance liquidity in response to the pandemic, including salary reductions and suspending share repurchases, and further strengthened its financial position with additional debt financing in April 2020. While the company experienced some negative impacts from COVID-19 late in the quarter, particularly affecting elective veterinary procedures and thus CAG instrument sales, overall financial performance remained resilient. The company's strong recurring revenue model, coupled with disciplined cost management and a strengthened liquidity position, positions it to navigate the ongoing uncertainties. Investors should note the company's forward-looking statements highlighting the continued evolution of COVID-19's impact and the company's proactive measures to maintain operations and financial flexibility.
Financial Highlights
52 data points| Revenue | $626.34M |
| Cost of Revenue | $266.75M |
| Gross Profit | $359.59M |
| R&D Expenses | $33.31M |
| Operating Income | $144.32M |
| Interest Expense | $7.69M |
| Net Income | $111.86M |
| EPS (Basic) | $1.31 |
| EPS (Diluted) | $1.29 |
| Shares Outstanding (Basic) | 85.43M |
| Shares Outstanding (Diluted) | 86.70M |
Key Highlights
- 1Total revenue increased by 8.7% to $626.3 million, driven by strong performance across segments, particularly CAG.
- 2Companion Animal Group (CAG) segment revenue grew 8.5% to $551.0 million, with CAG Diagnostics recurring revenue up 10.0% organically.
- 3The company proactively managed costs in response to COVID-19, including temporary salary reductions and suspending share repurchases.
- 4Liquidity was enhanced in April 2020 with a $200 million senior notes issuance and an expanded $1 billion Credit Facility.
- 5Net income attributable to IDEXX stockholders increased by 8.9% to $111.8 million, resulting in diluted EPS of $1.29, up from $1.17 in the prior year.
- 6The company continues to monitor and adapt to the evolving impacts of the COVID-19 pandemic, which began to affect business in mid-March.
- 7Gross profit margin saw a slight decrease of 20 basis points to 57.4% due to the initial impacts of COVID-19 and incremental investments, partially offset by strong sales volumes and pricing.